Bayer Receives FDA Fast Track Designation for asundexian Stroke Program
Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment…
Read More...
Read More...
